Celgene profit beats estimates as demand for cancer drugs rise
April 25 (Reuters) - Biotechnology firm Celgene Corp reported a first-quarter profit that edged past analysts' estimates on strong demand for its cancer drugs, Revlimid and Abraxane, and it raised its 2013 earnings forecast.
Net income fell to $384.9 million, or 89 cents per share, from $401.5 million, or 90 cents per share, a year earlier.
Excluding one-time items, it earned $1.37 per share. Analysts on average expected a profit of $1.35 per share, according to Thomson Reuters I/B/E/S.
- Exclusive: Secret contract tied NSA and security industry pioneer |
- Housing, jobs data weaken, but overall economic picture still upbeat
- Putin critic Khodorkovsky in Germany after pardon |
- Target probe looks overseas, stolen cards offered online
- Pizza outlet attacked as India, U.S. fail to cool diplomat row |